Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
inflammatory bowel disease
Biotech
Prometheus team returns with brand-new biotech and $400M
A brand-new biotech called Mirador has emerged from the team behind Prometheus Biosciences with a massive $400 million series A funding round.
Annalee Armstrong
Mar 21, 2024 7:00am
Surrozen stops IBD program due to dose concerns and competition
Jan 18, 2024 9:55am
GSK jilts Sosei, axing bowel disease drug amid immunology pivot
Nov 27, 2023 5:00am
Sanofi pays Teva $500M to join red-hot bowel disease race
Oct 4, 2023 6:00am
Surrozen culls 2 research programs as cash preservation persists
Aug 10, 2023 10:30am
Roche lining up $7B deal for Roivant's bowel disease drug: WSJ
Jul 14, 2023 7:30am